References
1. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term
Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice
From the American Gastroenterological Association.Gastroenterology. 2017;152(4):706-715.
2. Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the
clinical and demographic characteristics associated with high-intensity
proton pump inhibitor use. American Journal of Gastroenterology.2007;102(5):942.
3. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors.Bmj. 2008;336(7634):2-3.
4. Gomm W, von Holt K, Thomé F, et al. Association of Proton Pump
Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data
Analysis. JAMA Neurol. 2016;73(4):410-416.
5. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive
medication use and the risk for hospital-acquired pneumonia.Jama. 2009;301(20):2120-2128.
6. Schoenfeld AJ, Grady D. Adverse Effects Associated With Proton Pump
Inhibitors. JAMA internal medicine. 2016;176(2):172-174.
7. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors
and risk of type 2 diabetes: results from three prospective cohort
studies. Gut. 2020.
8. Yuan J, Zhang C, Sparks JA, et al. Regular use of proton pump
inhibitor and risk of rheumatoid arthritis in women: a prospective
cohort study. Aliment Pharmacol Ther. 2020;52(3):449-458.
9. Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term
use of proton pump inhibitors: expert review and best practice advice
from the American Gastroenterological Association.Gastroenterology. 2017;152(4):706-715.
10. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation
practice guidelines for chronic kidney disease: evaluation,
classification, and stratification. Annals of internal medicine.2003;139(2):137-147.
11. Global, regional, and national burden of chronic kidney disease,
1990-2017: a systematic analysis for the Global Burden of Disease Study
2017. Lancet. 2020;395(10225):709-733.
12. Kazancioğlu R. Risk factors for chronic kidney disease: an update.Kidney international supplements. 2013;3(4):368-371.
13. Tuttle KR, Alicic RZ, Duru OK, et al. Clinical Characteristics of
and Risk Factors for Chronic Kidney Disease Among Adults and Children:
An Analysis of the CURE-CKD Registry. JAMA Network Open.2019;2(12):e1918169-e1918169.
14. Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal Anti-Inflammatory
Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension:
Nationwide Longitudinal Cohort Study. Hypertension.2015;66(3):524-533.
15. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton
Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.J Am Soc Nephrol. 2016;27(10):3153-3163.
16. Helsel BC, Williams JE, Lawson K, Liang J, Markowitz J. Telemedicine
and Mobile Health Technology Are Effective in the Management of
Digestive Diseases: A Systematic Review. Dig Dis Sci.2018;63(6):1392-1408.
17. Al-Aly Z, Maddukuri G, Xie Y. Proton Pump Inhibitors and the Kidney:
Implications of Current Evidence for Clinical Practice and When and How
to Deprescribe. Am J Kidney Dis. 2020;75(4):497-507.
18. Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are
associated with increased risk of development of chronic kidney disease.BMC nephrology. 2016;17(1):1-8.
19. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump
inhibitors based on a large, multi-year, randomized trial of patients
receiving rivaroxaban or aspirin. Gastroenterology.2019;157(3):682-691. e682.
20. Losurdo G, Di Leo A, Leandro G. What Is the Optimal Follow-up Time
to Ascertain the Safety of Proton Pump Inhibitors?Gastroenterology. 2020;158(4):1175.
21. Simin J, Liu Q, Fornes R, Brusselaers N. Safety of proton pump
inhibitors questioned based on a large randomized trial of patients
receiving rivaroxaban or aspirin. Gastroenterology.2020;158(4):1172-1173.
22. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access
resource for identifying the causes of a wide range of complex diseases
of middle and old age. PLoS Med. 2015;12(3):e1001779.
23. Altman DG, Andersen PK. Calculating the number needed to treat for
trials where the outcome is time to an event. Bmj.1999;319(7223):1492-1495.
24. Qiu T, Zhou J, Zhang C. Acid-suppressive drugs and risk of kidney
disease: A systematic review and meta-analysis. Journal of
gastroenterology and hepatology. 2018.
25. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and
the risk of chronic kidney disease. JAMA internal medicine.2016;176(2):238-246.
26. Wijarnpreecha K, Thongprayoon C, Chesdachai S, Panjawatanana P,
Ungprasert P, Cheungpasitporn W. Associations of Proton-Pump Inhibitors
and H2 Receptor Antagonists with Chronic Kidney Disease: A
Meta-Analysis. Dig Dis Sci. 2017;62(10):2821-2827.
27. Desbuissons G, Mercadal L. Is red meat consumption the confounding
factor explaining the association between chronic kidney disease and
proton pump inhibitors? Nephrologie & therapeutique.2019;15(4):191-192.
28. Dai C, Jiang M, Cao Q. Proton‐Pump Inhibitor use and the risk of
Ischaemic Stroke. Journal of internal medicine.2018;283(3):330-330.
29. Prasad V, Jena AB. Prespecified Falsification End Points: Can They
Validate True Observational Associations? JAMA.2013;309(3):241-242.
30. Chen G, Ning LJ, Qin Y, Zhao B, Mei D, Li XM. Acute kidney injury
following the use of different proton pump inhibitor regimens: A
real-world analysis of post-marketing surveillance data. Journal
of gastroenterology and hepatology. 2021;36(1):156-162.
31. Tonelli M, Lloyd AM, Bello AK, et al. Statin use and the risk of
acute kidney injury in older adults. BMC nephrology.2019;20(1):1-9.
32. Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but
serious complication. Kidney international. 2013;83(4):553-556.
33. Dousdampanis P, Trigka K, Fourtounas C. Hypomagnesemia, chronic
kidney disease and cardiovascular mortality: pronounced association but
unproven causation. Hemodialysis international International
Symposium on Home Hemodialysis. 2014;18(4):730-739.
34. Sakaguchi Y, Shoji T, Hayashi T, et al. Hypomagnesemia in type 2
diabetic nephropathy: a novel predictor of end-stage renal disease.Diabetes Care. 2012;35(7):1591-1597.
35. Raghavan R, Shawar S. Mechanisms of Drug-Induced Interstitial
Nephritis. Advances in chronic kidney disease. 2017;24(2):64-71.
36. Perazella MA. Drug-induced acute kidney injury: diverse mechanisms
of tubular injury. Current opinion in critical care.2019;25(6):550-557.
37. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested
case-control study indicates an increased risk of acute interstitial
nephritis with proton pump inhibitor use. Kidney international.2014;86(4):837-844.
38. Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between
proton pump inhibitor use and the risk of adverse kidney outcomes: a
systematic review and meta-analysis. Nephrol Dial Transplant.2018;33(2):331-342.
39. Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD.Journal of nephrology. 2016;29(5):611-616.
40. Ferrè S, Baldoli E, Leidi M, Maier JA. Magnesium deficiency promotes
a pro-atherogenic phenotype in cultured human endothelial cells via
activation of NFkB. Biochimica et biophysica acta.2010;1802(11):952-958.
41. Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors
alter the composition of the gut microbiota. Gut.2016;65(5):749-756.
42. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump
inhibitors and risk of type 2 diabetes: results from three prospective
cohort studies. Gut. 2020.
43. Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and
the brain-gut-kidney axis in hypertension and chronic kidney disease.Nature reviews Nephrology. 2018;14(7):442-456.